Publisher Correction: Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study

Affiliations

• ¹ Synlogic, Inc., Cambridge, MA, USA. [email protected].
• ² University of Pittsburgh, Pittsburgh, PA, USA.
• ³ UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA.
• ⁴ PRA Health Sciences, Salt Lake City, UT, USA.
• ⁵ Boston Children's Hospital, Boston, MA, USA.
• ⁶ Harvard Medical School, Boston, MA, USA.
• ⁷ Vanderbilt University Medical Center, Nashville, TN, USA.
• ⁸ Human Predictions LLC, Boston, MA, USA.
• ⁹ Metabolic Solutions, Nashua, NH, USA.
• ¹⁰ Synlogic, Inc., Cambridge, MA, USA.